← Back to Search

TGF-β Inhibitor

AVID200 for Primary Myelofibrosis

Phase 1
Waitlist Available
Research Sponsored by John Mascarenhas
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Life expectancy of at least six months
At least two weeks must have elapsed between the last dose of any MF-directed drug treatments (including investigational therapies and excluding hydroxyurea) and study enrollment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 37 days after 13 cycles (each cycle is 21 days)
Awards & highlights

Study Summary

This study is evaluating whether a drug called AVID200 can reduce the amount of fibrosis in people with myelofibrosis.

Eligible Conditions
  • Primary Myelofibrosis
  • Myelofibrosis
  • Post-Extubation Mucus Formation

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 37 days after 13 cycles (each cycle is 21 days)
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 37 days after 13 cycles (each cycle is 21 days) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximally tolerated dose (MTD) of AVID200
Number of patients with response eligibility for Phase 1b
Secondary outcome measures
Bone marrow fibrosis grade
EORTC QLQ-C30
IWG/ELN criteria
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: AVID200Experimental Treatment1 Intervention
intravenous in dose cohorts of 70mg/m2 or 180 mg/m2
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AVID200
2019
Completed Phase 1
~30

Find a Location

Who is running the clinical trial?

John MascarenhasLead Sponsor
9 Previous Clinical Trials
209 Total Patients Enrolled
7 Trials studying Primary Myelofibrosis
147 Patients Enrolled for Primary Myelofibrosis
Formation BiologicsIndustry Sponsor
3 Previous Clinical Trials
92 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,627 Previous Clinical Trials
40,927,320 Total Patients Enrolled
69 Trials studying Primary Myelofibrosis
6,820 Patients Enrolled for Primary Myelofibrosis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby Mar 2025